Sintx Technologies acquires SiNAPTIC surgical assets for $750,000 in shares

SINTX Technologies (SINT) has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX’s strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in the foot and ankle fusion market. Under the terms of the agreement, SINTX has acquired all intellectual property, product designs, and development assets related to six differentiated foot and ankle implant systems. These designs are backed by clinical development and mechanical testing and a 510(k) pre-submission that is expected to accelerate near-term commercial launch activities. The global ankle fusion market, currently valued at approximately $750.5 million, is expected to grow to $1.38 billion by 2032, representing a CAGR of 9.1%, according to industry research. As part of the transaction, key members of the SiNAPTIC Surgical executive team and board of directors will join SINTX in the following roles: Chairman of SINTX Clinical Advisory Board, Bryan Scheer, M.D.; Managing Director of Business Development, Hugh Roberts; Chief Commercial Officer, Lisa Marie Del Re, MPE, ATC, NASM-PES;Senior Vice President of Regulatory and Quality Affairs, Brian Hockett; Senior Design Engineer, Basil Tharu, M.S.. In consideration for the acquired assets, SINTX issued $750,000 in common shares , priced at $3.465 per share which represents a 10% premium to the closing price of the Company’s common stock on Friday, June 20, 2025, along with 325,000 performance-based common stock purchase warrants. The common shares are subject to a six-month lock-up agreement and the Company has committed to file a resale registration statement with the Securities and Exchange Commission registering the resale of the common shares and the common shares issuable on exercise of the common stock purchase warrants. These warrants are exercisable over five years at a strike price of $6.30, and vest upon achieving specific regulatory and commercial milestones, including FDA clearance and revenue targets. SINTX will manufacture all devices under its FDA-registered and ISO-certified quality system and leverage existing FDA clearances and Master Files to streamline regulatory approvals. In addition, Dr. Bryan Scheer, Chairman and CEO of SiNAPTIC, will lead a newly formed Clinical Advisory Board to guide ongoing product development and surgeon engagement.